Share on StockTwits

Prothena Co. PLC (NASDAQ:PRTA) Insider Tara Nickerson acquired 1,656 shares of Prothena Co. PLC stock on the open market in a transaction dated Monday, May 12th. The stock was purchased at an average cost of $21.00 per share, with a total value of $34,776.00. Following the transaction, the insider now directly owns 2,000 shares of the company’s stock, valued at approximately $42,000. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Prothena Co. PLC (NASDAQ:PRTA) traded up 7.64% during mid-day trading on Monday, hitting $20.86. 295,156 shares of the company’s stock traded hands. Prothena Co. PLC has a 52-week low of $8.20 and a 52-week high of $49.24. The stock’s 50-day moving average is $30.41 and its 200-day moving average is $29.57. The company’s market cap is $456.9 million. Prothena Co. PLC also was the recipient of a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 763,327 shares, an increase of 41.4% from the April 15th total of 539,731 shares. Based on an average daily trading volume, of 835,091 shares, the days-to-cover ratio is currently 0.9 days. Currently, 3.5% of the company’s stock are sold short.

Prothena Co. PLC (NASDAQ:PRTA) last released its earnings data on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.81 by $0.03.

A number of research firms have recently commented on PRTA. Analysts at Wedbush upgraded shares of Prothena Co. PLC to a “best ideas list” rating in a research note on Friday, April 25th. Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Prothena Co. PLC in a research note on Thursday, April 24th. They now have a $60.00 price target on the stock. Finally, analysts at Citigroup Inc. initiated coverage on shares of Prothena Co. PLC in a research note on Wednesday, April 9th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $43.75.

Prothena Corporation PLC is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.